Jiayi Powder Veterinary Grade API is released as a bulk crystalline active pharmaceutical ingredient for veterinary drug product manufacture across seven dosage platforms: tablets, injections, capsules, powders, granules, premix and solutions. It is supplied under product codes JY-VG-O, JY-VG-P and JY-VG-M; these suffixes denote oral solid, parenteral and medicated premix grades, respectively. Each lot is released with a certificate of analysis and documentation that the API has been produced under ICH Q7 conditions and controlled against compendial microbial and physicochemical limits. The product is not a finished dosage form and must be formulated by a licensed veterinary drug manufacturer using compatible excipients and process validation.

Specifications are established for assay, related substances, water content, residue on ignition, residual solvents, elemental impurities and particle-size distribution. Differences from commodity veterinary APIs are observed in release data: the product includes a controlled D90 for the intended dosage form, a reduced-endotoxin option for parenterals, and residual solvent certification according to USP <467>. Commodity suppliers may ship against assay and moisture alone; this product is intended for manufacturers that require tighter control of blend uniformity, compendial parenteral safety limits and premix dispersion.

Physical and Chemical Specifications for Multi-Dosage-Form Compatibility

The release profile is designed to cross-link the same API to multiple veterinary manufacturing routes. A single chemical entity may satisfy assay requirements but still fail downstream processing because of uncontrolled particle shape, endotoxin load or residual solvent profile. The specifications below are applied by grade and are reviewed against the maximum intended species-specific dose.

These limits may be tightened or relaxed by the finished-product manufacturer only after process-capability and stability data justify the change. The inclusion of particle-size and density testing is a material difference from commodity APIs released primarily by assay and loss on drying. For oral powder and granule applications, the acceptance limits for particle size are selected to reduce segregation into high-speed filling equipment. For injectable manufacture, endotoxin is controlled on the API because downstream depyrogenation cannot be assumed to remove a heavily contaminated input without altering assay or increasing related substances.

What Limits Direct Compression Uniformity in Low-Dose Veterinary Tablets?

In veterinary tablet production, blend uniformity failures frequently originate from particle-size mismatch between the API and direct-compression excipients. When the active is present at less than 1.0% of tablet mass, the API must be deagglomerated and distributed onto carrier particles with sufficient shear. The JY-VG-O grade is controlled with D90 ≤75 µm and a Hausner ratio ≤1.35 to reduce segregation in bin blenders and force-fed tablet presses. A grade with a wider or uncontrolled particle-size distribution may produce stratified blends, leading to content uniformity failures under USP <905>. Direct compression trials should evaluate 10-minute and 30-minute blend samples from the discharge port and tablet samples from beginning, middle and end of compression to quantify segregation. Tablet press settings such as turret speed and feed-frame paddle speed require adjustment; excessive feed-frame speed can reintroduce fines and cause weight variation greater than ±5.0% for low-dose cores. Precompression force is typically maintained between 5 kN and 15 kN, depending on the formulation, to minimize capping while allowing particle rearrangement before main compression.

Excipient order of addition is not minor in low-dose tablet manufacture. A proven sequence is to premix the API with a portion of fine carrier such as microcrystalline cellulose, pass the premix through a 500 µm screen, then add the remaining fillers and lubricants. Magnesium stearate should be added last and blended for 3–5 minutes; extended lubrication can reduce tablet tensile strength and prolong disintegration. If the product contains hygroscopic excipients, processing should be conducted below 60% RH, and the API should be pre-dried at 40–50 °C in a fluid-bed dryer when loss on drying exceeds 1.0%. These operational boundaries prevent the most common failures observed on production-scale rotary presses: lamination at precompression, weight variability at high turret speed, and assay drift across the batch.

With injectable solution manufacture, the JY-VG-P grade is intended for dissolution in Water for Injection after pH adjustment. Dissolution is performed in a jacketed stainless-steel vessel meeting ASME BPE surface finish requirements, with nitrogen overlay if oxidation is confirmed by forced degradation data. The solution is filtered through a 0.22 µm sterilizing-grade membrane filter, and the filtrate is held in a sterile receiving tank before aseptic filling. Endotoxin control begins with the API: the acceptance limit of ≤0.25 EU/mg is derived from the maximum intended veterinary dose and should be verified during process validation. Post-filtration, the finished injection must meet USP <788> particulate matter requirements and USP <789> for ophthalmic solutions if that route is used. Buffering and antioxidant selection should avoid amine-based stabilizers if the API contains ester or lactone functional groups; published data for this specific configuration are limited, so forced degradation studies in the final formulation are required before commercial use.

For injectable suspension formulations, the particle-size requirement is stricter than for oral solids. The injectable grade is controlled with D90 ≤10 µm because larger particles can block hypodermic needles, cause injection-site reactions or settle into a non-resuspendable sediment. Viscosity modifiers and wetting agents are introduced after the API is wetted, and the suspension is passed through a high-shear mixer before final homogenization. The process should be sampled for particle-size distribution after each homogenization pass; if D90 increases by more than 15% after 24 hours at 25 °C, the suspension is not physically stable and the formulation must be reworked.

When the API Is Co-Milled with Lactose Monohydrate for Premix Manufacturing

For medicated premix and granulated powders, the API may be co-milled with lactose monohydrate or a starch-cellulose carrier to achieve a uniform premix before feed incorporation. The particle-size control of the JY-VG-M grade is directed at dispersion in high-shear mixers with ploughshare impellers and chopper blades. If the API D90 is ≤75 µm, co-milling at low impeller speed for 3–8 minutes is usually sufficient to reach a relative standard deviation of ≤5.0% in assay when sampled from 10 locations. Overmilling can generate fines that increase dust loss and reduce flow into feed mills. The process should be controlled by power draw rather than time alone; a sharp decrease in mixer torque may indicate particle attrition and segregation.

For granulated premix, wet granulation with purified water or a low-viscosity binder solution at 20–30% w/w liquid addition may be used, followed by fluid-bed drying at 60–70 °C inlet air temperature and final sieving through a 150 µm screen. The dried granules should be tested for loss on drying ≤2.0% and for sieve distribution. Unlike commodity APIs that are milled only to a coarse powder, this controlled grade reduces the need for high-shear milling in the finished premix, which is a source of cross-batch assay drift. In feed mills, the premix is further diluted in a ribbon mixer or vertical screw mixer; sampling points should include the top, middle and discharge zones to detect density-driven segregation.

Stability studies for veterinary products must follow the VICH stability guidelines. For the API alone, storage at 25 °C with excursion to 40 °C may be evaluated under VICH GL3; if the veterinary product is intended for tropical markets, 30 °C/65% RH long-term and 40 °C/75% RH accelerated conditions are applied under VICH GL5. A forced degradation study should include acid hydrolysis at 0.1 N HCl, base hydrolysis at 0.1 N NaOH, peroxide oxidation at 3% hydrogen peroxide, thermal stress at 70 °C, and photolysis per ICH Q1B. The API should be stored in sealed double polyethylene bags inside a fiber drum with desiccant if ambient relative humidity exceeds 60% RH. Avoid storage in uncoated aluminum containers when chloride or oxidative residues are present; incompatibility with metal surfaces should be confirmed during packaging qualification.

Residual Solvents and Elemental Impurities Are Controlled Across All Grades

Residual solvents are tested by headspace gas chromatography according to USP <467> and Ph. Eur. 5.4. Solvents classified as Class 1 in ICH Q3C are controlled at ≤2 ppm or not detected with a validated limit. Class 2 solvents are reviewed against the permitted daily exposure for the maximum species-specific dose; if a solvent is not used in the final crystallization, the limit may be set at ≤0.5% as a default. Elemental impurities are measured by inductively coupled plasma mass spectrometry following USP <233> sample digestion. Limits are assigned by route: oral and injectable grades have separate elemental risk assessments per ICH Q3D. The most conservative limit set is generally used for injectable grade because the same material may be diluted before administration. This dual testing is not universal in veterinary API supply chains and represents a process difference from products released only by wet chemistry.

For oral solution and suspension compounding, the API is dispersed in a buffered vehicle under high-shear mixing. Preservative compatibility must be evaluated with paraben, benzoic acid, or sorbic acid systems using a challenge test such as Ph. Eur. 5.1.3 or USP <51>. Solutions may be filled into amber glass or high-density polyethylene bottles; light protection is required if the API shows photolytic degradation. The release specification for finished solutions should include pH, assay, clarity, preservative content and deliverable volume. Process validation should confirm that the API is fully dissolved or uniformly suspended after 15–30 minutes of mixing and that no visible agglomerates form after 24 hours at 25 °C. The JY-VG-O and JY-VG-P grades differ in particle size and endotoxin control; selecting the correct grade is necessary because a parenteral grade may be too fine for dry powder filling and an oral grade may not meet injectable endotoxin limits.